NEW YORK, Aug. 21, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that it has filed a patent application for a new mechanical method to separate stromal vascular fraction (SVF) from the blood vessels in adipose tissue (fat) to be used clinically in regenerative medicine.
The provisional patent, titled, "ISOLATION OF STROMAL VASCULAR FRACTION FROM THE BLOOD VESSELS IN ADIPOSE TISSUE USING HOMONOGENATION, A MECHANICAL METHOD" expands the patent portfolios of IntelliCell in mechanical methods to isolate/separate SVF from blood vessels in adipose tissue.
According to IntelliCell's Chairman/CEO Steven Victor MD, "This will strengthen our position in new and different methods of separation of SVF from the blood vessels in adipose tissue. We feel that using a mechanical means of separation of SVF is superior to that by using enzymes since the time and cost are vastly reduced and you do not have to worry about endotoxins in the specimen. I also believe by using mechanical methods of separation we fall within the 'minimally manipulated' guidelines of the FDA CFR 1271.10."
Sarah Young, Director of Quality Assurance stated, "This is another exciting discovery in that we have been able to take a technology and develop a protocol to separate SVF so we can have viable cells. This is a significant advancement in the mechanical method of cell separation."
IntelliCell recognizes the future of cellular medicine in SVF therapy. These are vascular cells residing in the walls of all blood vessels in the body and the IntelliCell process will soon harvest these cells from non-living adipose tissue. In the future as part of this homologous process,
Dr. Victor said, "The future of medicine has reached an exciting stage with the knowledge that SVF can be used clinically to treat patients for a number of disease states with high unmet clinical needs."
About IntelliCell BioSciencesIntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Forward-Looking StatementsCertain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Contacts:IntelliCell BioSciences, Inc.Rubenstein Investor RelationsContact: Tim ClemensenEmail Contact: TClemensen@rubensteinir.com(212) 843-9337
SOURCE IntelliCell BioSciences, Inc.